Kura Oncology (KURA) Stock Forecast & Price Target

Kura Oncology is viewed favorably because KOMZIFTI’s launch is showing real commercial traction, with 115 new patient starts, >250 total prescriptions, roughly 40% combination use, and strong payer access that helped capture the majority of new patient starts in r/r NPM1-mutant AML. Fundamentally, the investment case is strengthened by ziftomenib’s emerging profile as a backbone therapy in AML, supported by KOMET-007 data showing 96% CRc in NPM1-mutant patients, 94% 12-month OS, durable responses that were not yet reached, and a safety profile consistent with 7+3 without additive myelosuppression. The balance sheet also supports execution, with $519MM of cash, expected collaboration payments, and multiple 2026 and 2027 clinical catalysts across frontline AML and solid-tumor programs that broaden the addressable market well beyond the initial relapse/refractory setting.

Kura Oncology is viewed negatively because its lead assets face substantial clinical risk, with ziftomenib in AML potentially proving less efficacious than expected and its safety profile no more differentiated than competitors, which would sharply reduce confidence in the pipeline. The company also depends on uncertain biomarker identification, FDA and foreign regulatory approvals, and patent strategies for tipifarnib, any of which could delay or prevent commercialization in a highly competitive oncology market. Although Kura is currently well-funded with cash, cash equivalents, and short-term investments, it may still need additional equity financing or non-dilutive capital to advance development and commercialization, raising dilution and execution risk.